D46.20 Refractory anemia with excess of blasts, unspecified

Name of the Condition

• Refractory anemia with excess of blasts, unspecified

Summary

Refractory anemia with excess of blasts, unspecified is a subtype of myelodysplastic syndrome (MDS) characterized by ineffective blood cell production in the bone marrow, leading to low blood cell counts (cytopenias) and abnormal cell development. The condition is termed "refractory" because it does not respond to standard treatments for anemia. It is distinguished by the presence of an increased number of immature blood cells (blasts) in the bone marrow and blood, and it carries a higher risk of progressing to acute myeloid leukemia (AML) compared to other MDS subtypes.

Causes

The exact cause of refractory anemia with excess of blasts, unspecified is often unknown. It may involve genetic mutations that disrupt normal blood cell production. Other factors can include previous chemotherapy or radiation therapy, exposure to certain chemicals (e.g., benzene), and rarely, inherited bone marrow failure syndromes.

Risk Factors

• Age (most common in individuals over 60)
• Previous cancer treatment with chemotherapy or radiation
• Exposure to industrial chemicals like benzene
• Family history of MDS or other blood disorders
• Certain genetic conditions (e.g., Fanconi anemia)

Symptoms

• Fatigue or weakness
• Frequent infections
• Easy or unexplained bruising or bleeding
• Shortness of breath
• Pale skin
• Unexplained weight loss

Diagnosis

Diagnosis involves a complete blood count (CBC) to identify cytopenias, followed by a bone marrow biopsy to assess cell dysplasia and blast count. Cytogenetic analysis may be performed to detect chromosomal abnormalities, and additional tests may be used to rule out other conditions.

Treatment Options

Treatment depends on the severity of the condition and the patient’s overall health. Options may include blood transfusions, growth factors to stimulate blood cell production, chemotherapy, and in some cases, stem cell transplantation. Supportive care to manage symptoms, such as antibiotics for infections or medications to control bleeding, is also common.

Prognosis and Follow-Up

Prognosis varies based on factors like blast count, cytogenetic findings, and patient age. Regular follow-up is essential to monitor blood counts, assess disease progression, and adjust treatment as needed. The risk of progressing to acute myeloid leukemia is higher in this subtype compared to other MDS types.

Complications

• Progression to acute myeloid leukemia (AML)
• Severe anemia requiring frequent transfusions
• Increased risk of infections due to low white blood cell counts
• Bleeding complications from low platelet counts

Lifestyle & Prevention

While lifestyle changes cannot prevent the condition, maintaining overall health may help manage symptoms. This includes avoiding exposure to known toxins (e.g., benzene), following a balanced diet, and practicing good hygiene to reduce infection risk. Regular medical check-ups are important for early detection of complications.

When to Seek Professional Help

Seek medical attention if you experience persistent fatigue, unexplained bruising or bleeding, frequent infections, or shortness of breath. These symptoms may indicate worsening cytopenias or disease progression and require prompt evaluation.

Tips for Medical Coders

When coding for refractory anemia with excess of blasts, unspecified (D46.20), ensure documentation supports the diagnosis, including bone marrow findings and blast count. Verify that the condition is not specified as RAEB-1 or RAEB-2, as those have distinct blast percentage criteria. Confirm the absence of other MDS subtypes or related conditions to avoid miscoding.